Neurotensin (NTS) is a 13-amino-acid peptide that functions as both a neurotransmitter and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor (GPCR). In the brain, NTS modulates the activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake; in the gut, NTS regulates a range of digestive processes. Here we present the structure at 2.8 Å resolution of Rattus norvegicus NTSR1 in an active-like state, bound to NTS 8-13 , the carboxy-terminal portion of NTS responsible for agonist-induced activation of the receptor. The peptide agonist binds to NTSR1 in an extended conformation nearly perpendicular to the membrane plane, with the C terminus oriented towards the receptor core. Our findings provide, to our knowledge, the first insight into the binding mode of a peptide agonist to a GPCR and may support the development of non-peptide ligands that could be useful in the treatment of neurological disorders, cancer and obesity.
Neurotensin (NTS) is a 13-amino-acid peptide that functions as both a neurotransmitter and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor (GPCR). In the brain, NTS modulates the activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake; in the gut, NTS regulates a range of digestive processes. Here we present the structure at 2.8 Å resolution of Rattus norvegicus NTSR1 in an active-like state, bound to NTS [8] [9] [10] [11] [12] [13] , the carboxy-terminal portion of NTS responsible for agonist-induced activation of the receptor. The peptide agonist binds to NTSR1 in an extended conformation nearly perpendicular to the membrane plane, with the C terminus oriented towards the receptor core. Our findings provide, to our knowledge, the first insight into the binding mode of a peptide agonist to a GPCR and may support the development of non-peptide ligands that could be useful in the treatment of neurological disorders, cancer and obesity.
Neurotensin (NTS) is a short peptide that is found in the nervous system and in peripheral tissues 1 . NTS shows a wide range of biological activities and has important roles in Parkinson's disease and the pathogenesis of schizophrenia, the modulation of dopamine neurotransmission, hypothermia, antinociception, and in promoting the growth of cancer cells [2] [3] [4] [5] [6] . Three neurotensin receptors have been identified. NTSR1 (ref. 7) and NTSR2 (ref. 8) belong to the class A GPCR family, whereas NTSR3 (also called SORT1) is a member of the sortilin family with a single transmembrane domain 9 . Most of the known effects of NTS are mediated through NTSR1 (ref. 5) , which signals preferentially via the G q protein. Many aspects of ligand binding to NTSR1 have been addressed by mutagenesis and modelling [10] [11] [12] but the details of ligand binding remain poorly understood at the molecular level. This has limited the rational design of compounds targeting NTSR1 for therapeutic purposes 5 in the absence of structural information on NTSR1 in complex with agonist or antagonist.
Recent progress in elucidating GPCR structures in complex with either small-molecule antagonists, agonists, or in complex with a heterotrimeric G protein has provided detailed molecular insights into GPCR function (reviewed in refs [13] [14] [15] . However, most receptor structures are of GPCRs belonging to the a group of class A (ref. 16 ), which characteristically bind small endogenous agonists deep within the transmembrane core. NTSR1 belongs to a large family of peptide receptors in the b group of class A GPCRs 16 ( Supplementary Fig. 1 ) that includes receptors for substance P, cholecystokinin, neuropeptide Y, endothelin and oxytocin. These peptide receptors bind agonists of a wide range of sizes, from a few amino acid residues to over 60. Current structural information on peptide receptors is limited to representatives of the c group of class A GPCRs 16 , namely the opioid receptors [17] [18] [19] [20] and a chemokine receptor 21 , all bound to non-peptidic drug-like antagonists. The CXCR4 receptor has also been crystallized in the presence of a cyclic peptide antagonist 21 . Although the structural understanding of peptide receptors has advanced, structures of peptide GPCRs from the b group have not yet been reported. In addition, no structures have been presented of a GPCR bound to a peptide agonist and only the structures of rhodopsin 22, 23 and the adenosine A 2A receptor (A 2A R) 24 have been determined bound to endogenous agonists. Here we present the crystal structure of Rattus norvegicus NTSR1 from the b GPCR subfamily bound to the C-terminal portion (NTS [8] [9] [10] [11] [12] [13] ) of the endogenous agonist NTS.
Structure determination of the agonist-bound NTSR1
Wild-type NTSR1 is unstable in detergent solution and hence is a difficult target for structural studies, particularly in the agonist-bound state which is generally thought to be less stable than the antagonistbound state 25 . The first step was therefore to stabilize NTSR1 using the strategy of conformational thermostabilization 26 . Previous work had generated a thermostable mutant of NTSR1, but the purified receptor was found to be unsuitable for crystallization, possibly because the receptor contained mutations that were selected in the unliganded state 27 . NTSR1 was therefore thermostabilized in the presence of the agonist NTS through the inclusion of six stabilizing mutations (mutant NTSR1-GW5; A86L 1.54 , E166A 3.49 , G215A ECL2 , L310A 6.37 , F358A 7.42 and V360A 7.44 , where superscripts are the Ballesteros-Weinstein numbers 28 ) ( Supplementary Fig. 2 and Supplementary  Table 1 ). Pharmacological characterization of NTSR1-GW5 (Supplementary Fig. 3 , Supplementary Table 2 and Supplementary Discussion) showed that the affinity for the agonist NTS was similar to that of the wild-type receptor, but that the apparent affinity for the neutral antagonist SR48692 and the sensitivity to Na 1 ions was lower. In G protein coupling assays, NTSR1-GW5 did not catalyse nucleotide exchange at Ga q in response to NTS ( Supplementary Fig. 3 ), indicating that the stabilizing mutations may have limited the ability to propagate the agonist-induced conformational change at the ligand-binding pocket to the re-arrangement of the intracellular face of the receptor required for G protein binding and activation.
For crystallization of NTSR1-GW5, T4 lysozyme (T4L) was engineered into intracellular loop 3 (ICL3) to improve the probability of obtaining well-diffracting crystals 29 . NTSR1-GW5-T4L was expressed in insect cells using the baculovirus expression system, solubilized and purified in lauryl maltose neopentyl glycol and crystallized using the lipidic cubic phase methodology 30 . Diffraction data were collected to 2.8 Å resolution from a single crystal and used to determine the structure by molecular replacement (Supplementary Table 3 , Supplementary  Fig. 4 and Supplementary Fig. 5 ). The final model of NTSR1-GW5-T4L, refined to R/R free values of 0.23/0.28, includes 454 residues, 2 HEPES molecules, 23 H 2 O molecules and the agonist ligand NTS [8] [9] [10] [11] [12] [13] .
Overall structure of NTSR1-GW5-T4L
The receptor core has seven transmembrane helices (TM1-TM7) ( Fig. 1 and Supplementary Fig. 6 ), as expected, but there was no density corresponding to amphipathic helix 8 at the C terminus of the receptor. Helix 8 has been observed in all GPCR structures except for the chemokine receptor CXCR4 (ref. 21) , so the absence of helix 8 in the structure of NTSR1-GW5-T4L could be because either NTSR1 in vivo does not possess helix 8 or this is the result of a crystallization artefact. On the intracellular side, TM7 is elongated by three helical turns beyond the conserved NP 7.50 XXY 7.53 motif, whereas other GPCRs have only one helical turn. This extension of TM7 is associated with the intracellular end of TM6 through hydrogen bonds between the side chain atoms of N375 and Q378 to the backbone carbonyl oxygen of A302 6.29 (Supplementary Fig. 7 ).
Of the intracellular loops in NTSR1, ICL1 was disordered (K93-Q96), ICL3 was disrupted through insertion of T4L, and only ICL2 showed density for a structural element, a short p-helix ( Fig. 1 ). ICL2 is thought to be important for G protein coupling, and the short helix in NTSR1 is similar to those observed in identical positions in both the inactive state 31 and in active states 32, 33 of b-adrenergic receptors (bARs). In the b 1 -adrenergic receptor (b 1 AR) 31 , the helix in ICL2 is stabilized by the interaction of a tyrosine residue in the middle of the helix that forms a hydrogen bond with the aspartate residue of the conserved D/ER 3.50 Y sequence in TM3. In NTSR1, K178 in the middle of the p-helix in ICL2 may perform a similar function, although its side chain is disordered, probably because the stabilizing mutation E166A 3.49 prevents the formation of the salt bridge. The extracellular surface of NTSR1 is composed of three short extracellular loops (ECL1, ECL2 and ECL3) and the N-terminal residues N52-D60 that extend across the receptor to form one side of the ligand-binding pocket (see below). The longest loop is ECL2, which contains two short antiparallel b-strands that are linked to TM3 by a disulphide bond between the conserved residues C142 3.25 and C225 ECL2 . These b-strands are characteristic of all the peptide GPCR structures determined so far.
NTSR1-GW5-T4L contains six thermostabilizing mutations and none of these residues is in the NTS binding pocket ( Fig. 1 ). Three of these mutations may directly affect the equilibrium between inactive and active states of NTSR1. The mutation F358A 7.42 is located at the kink in TM7, with the alanine side chain pointing into the receptor core, and the F358A mutant is known to be constitutively active 34 . The mutation E166A 3.49 is in the conserved D/ER 3.50 Y motif in TM3 and will prevent the formation of the intrahelical salt bridge with R167 3.50 , thus facilitating the transition to the active state 35, 36 by allowing R167 3.50 to interact with N257 5.58 . The R167-N257 interaction may be promoted by the L310A 6.37 mutation through decreasing the size of the side chain. The reasons for the thermostabilizing effect of the A86L 1.54 , V360A 7.44 and G215A ECL2 mutations are not obvious, although it is interesting that an alanine residue 37 is found in human NTSR1 ( Supplementary  Fig. 8 ) at the position equivalent to G215 in rat NTSR1.
NTSR1-GW5 is in an active-like conformation
Upon agonist binding, a GPCR undergoes conformational changes that ultimately allow binding and activation of a G protein at the 
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intracellular surface of the receptor. Agonist-induced conformational changes in the ligand-binding pocket are largely receptor specific and thought to be relatively small, leading to larger conformational changes in the intracellular half of the receptor 13 . There are no reported structures of NTSR1 in an inactive conformation, so we are unable to discuss agonist-specific conformational changes in the ligand-binding pocket. However, it is possible to compare the NTSR1 structure to the inactive and active conformations of rhodopsin and b 2 AR. This allows an assessment of the overall conformation of NTSR1 and, in addition, the rotamer conformations of mechanistically important residues that show characteristic interactions depending on whether the receptor is in an inactive or active state. These comparisons indicate that NTSR1 is in an active-like state. One of the major conformational changes occurring during the transition from the inactive to an active state is an outward tilt of TM6 at the intracellular face of the GPCR. The extent of movement of TM6 upon activation is 6 Å for rhodopsin and 11-14 Å for b 2 AR 32 , with TM6 of NTSR1 in a position similar to that seen for the active states of rhodopsin 22, 38 (Fig. 2) . The distance between the Ca atoms of R 3.50 and E 6.30 change upon activation from 9 Å to 15 Å in rhodopsin 22, 39 , and from 11 Å to 19 Å in b 2 AR 32, 40 . The equivalent distance in NTSR1 is 14 Å .
Other features of NTSR1 are also remarkably similar to those found in the active conformations of rhodopsin and b 2 AR. In inactive receptor conformations, R 3.50 of the D/ERY motif forms an intrahelical salt bridge with D/E 3.49 , which is, for example, present in the inactive structure of the nociceptin/orphanin FQ receptor (NOP) 19 (Fig. 3) , which is the closest structural homologue of NTSR1 among peptide receptors. Upon activation, the D/E 3.49 -R 3.50 salt bridge is broken and R 3.50 re-orients to form an interhelical hydrogen bond with the conserved tyrosine residue Y 5.58 , linking TM3 and TM5 (ref. 13 ). In NTSR1, the R167 3.50 side chain is hydrogen bonded to N257 5.58 that interacts with the conserved residue S164 3.47 (Fig. 3 ), stabilizing TM5 in an active-like orientation 35 . In addition, Y369 7.53 of the highly conserved NP 7.50 XXY 7.53 motif occupies space within the helical bundle as seen for Y 7.53 in the active states of rhodopsin and b 2 AR (Fig. 3) . In contrast to the active rhodopsin and b 2 AR, Y369 7.53 in NTSR1 does not pack against R167 3.50 , suggesting that N257 5.58 has a greater contribution to the active state stabilization than Y369 7.53 (ref. 35 ).
Comparison of the NTSR1 structure with rhodopsin and b 2 AR suggests that it is in an active-like state, indicating that it may couple effectively to G proteins. NTSR1-GW5-T4L, as expected, does not couple to G protein ( Supplementary Fig. 3 ), because T4L replaces most of ICL3, which is essential for G protein binding, and sterically blocks access to the intracellular surface of the receptor. Surprisingly, NTSR1-GW5 that contains the wild-type ICL3 also does not catalyse nucleotide exchange at Ga q in response to NTS ( Supplementary  Fig. 3 ). This may be a consequence of the extended region of TM7 on the intracellular surface forming an interhelical contact with TM6 ( Supplementary Fig. 7 ). This appears to occlude the cavity at the intracellular face of the receptor where the C-terminal portion of the Ga protein binds to fully active receptors 22, 23, 32, 38 . Thus, although the structure of NTSR1 contains many features of an active receptor it is possible that the intracellular surface of the receptor does not represent the structure of fully active NTSR1.
The NTS [8] [9] [10] [11] [12] [13] binding site NTSR1-GW5-T4L was co-crystallized with NTS [8] [9] [10] [11] [12] [13] , which has higher potency and efficacy than full-length NTS 10,41 , although it does not exist in vivo. NTSR1 also binds the NTS-related hexapeptide neuromedin N, which is produced along with NTS during proteolytic processing of the proNTS precursor 5 . The amino acid sequence of neuromedin N (KIPYIL) is similar to NTS 8-13 (RRPYIL). Potent NTS analogues that can cross the blood-brain barrier (for example, derivatives of RKPWLL) can also be synthesized (see ref. 5 ). The similarity of these agonists to NTS [8] [9] [10] [11] [12] [13] indicates that they all bind in a similar manner. There is charge complementarity between NTS 8-13 and its binding pocket, with the positive-charged arginine side chains of NTS [8] [9] [10] [11] [12] [13] adjacent to the electronegative rim of the binding site, and the C terminus of NTS [8] [9] [10] [11] [12] [13] is predicted to form a salt bridge with R327 6.54 ( Fig. 4 and Supplementary Table 4 ). There are also extensive van der Waals interactions between NTS [8] [9] [10] [11] [12] [13] and the receptor along with hydrogen bonds and a salt bridge (Supplementary Table 4 , Supplementary Table 5 and Supplementary Fig. 9 ). It is striking that only three out of eight hydrogen bonds are made between the side chains of NTS [8] [9] [10] [11] [12] [13] and the receptor, with the bulk of receptor-ligand contacts being van der Waals interactions.
The ligand binding pocket for NTS [8] [9] [10] [11] [12] [13] is composed of amino acid residues in the N terminus, the three extracellular loops (ECL1-ECL3) and six transmembrane a-helices (TM2-TM7), with the greatest number of ligand-receptor contacts from residues in ECL2, ECL3, TM6 and TM7 (Supplementary Table 5 ). The binding pocket is wide open on the extracellular surface of NTSR1 ( Fig. 4 and Supplementary  Fig. 10 ) with density for NTS [8] [9] [10] [11] [12] [13] clearly discernable from a difference electron density map ( Supplementary Fig. 11 ), but we believe that radiation damage during data collection has resulted in reduced density for the C-terminal carboxylate group ( Supplementary Fig. 12 ). The extended conformation of NTS [8] [9] [10] [11] [12] [13] in the crystal structure is in good RESEARCH ARTICLE agreement with that of NTS [8] [9] [10] [11] [12] [13] bound to wild-type NTSR1 analysed by solid-state NMR 42 ( Supplementary Fig. 13 ). The overall shape of the NTSR1 ligand-binding pocket is narrower than that observed in the other peptide receptors [17] [18] [19] [20] [21] due to an inward shift of the extracellular regions of TM2 and TM6 ( Supplementary Fig. 14) , probably as a result of the pronounced kink in TM2 at A120 2.57 and a change in tilt of TM6. At the extracellular surface, the NTS [8] [9] [10] [11] [12] [13] binding pocket is partially capped by the ECL2 b-hairpin and the proximal end of the receptor N terminus. NTSR1 has been subjected to extensive sitedirected mutagenesis studies to define ligand-receptor interactions The quality of the electron density of NTS [8] [9] [10] [11] [12] [13] is depicted as blue isosurface (2F o 2 F c map contoured at 1s). b, Key NTSR1 residues (green residues with grey labels) in contact with the peptide ligand (grey residues with bold black labels). Hydrogen bonds and salt bridges are indicated by dashed lines (black). The electron density maps of selected NTSR1 residues (L55, Y146, T226, R327) are shown as blue isosurface (2F o 2 F c map contoured at 1s). c, The charge complementarity between NTS [8] [9] [10] [11] [12] [13] and its binding pocket is depicted with the NTSR1 surface coloured according to its electrostatic potential (24 kT e 21 to 14 kT e 21 ; red, negative; blue, positive). The positively charged arginine side chains of the ligand face the electronegative rim of the binding pocket, whereas the negatively charged carboxylate of L13 resides in an electropositive environment. See also Supplementary Information.
(see Supplementary Discussion) and there is excellent agreement between those data and the structure of NTSR1.
There is a striking difference between the binding mode of NTS [8] [9] [10] [11] [12] [13] in NTSR1 with the binding of agonists in rhodopsin, b 1 AR and A 2A R (Fig. 5) . The agonist-specific interactions made by isoprenaline in b 1 AR (ref. 43 ) and adenosine in A 2A R (ref. 24 ) all occur at a similar depth in the receptor with respect to the extracellular surface as retinal in rhodopsin 22, 23 . In contrast, NTS [8] [9] [10] [11] [12] [13] does not penetrate the receptor as deeply, with the C terminus of NTS 8-13 over 5 Å closer to the extracellular surface than the hydroxyl groups in isoprenaline and adenosine that are characteristic of agonists for bARs and A 2A R. This indicates that the mode of activation of NTSR1 is subtly different from these receptors. Structures of NTSR1 in the inactive state will be necessary to gain a better understanding of how peptide agonists activate GPCRs.
METHODS SUMMARY
The stabilized NTSR1 mutant with T4 lysozyme replacing most of intracellular loop 3 was expressed in insect cells and purified by cobalt affinity chromatography. It was crystallized in lipidic cubic phase. Diffraction data were collected at the GM/CA-CAT beamline of the Advanced Photon Source at the Argonne National Laboratory. The structure was solved by molecular replacement using data from a single crystal.
NTS [8] [9] [10] [11] [12] [13] All-trans-retinal Isoprenaline Adenosine CVX15 a b Isoprenaline Adenosine NTS [8] [9] [10] [11] [12] [13] All-All trans t -retinal ti l Expression of NTSR1 in insect cells. The baculovirus construct NTSR1-GW5-T4L consisted of the haemagglutinin signal peptide and the Flag tag 45 , followed by the thermostabilized rat NTSR1 (T43-K396 containing the mutations A86L, E166A, G215A, L310A, F358A, V360A) with the ICL3 residues H269-R299 replaced by the cysteine-free bacteriophage T4 lysozyme (N2-Y161 with the mutations C54T and C97A) and a GSGS linker. A deca-histidine tag was placed at the C terminus. NTSR1-GW5 contained the wild-type ICL3 sequence. Wildtype NTSR1 (Met-T43-Y424) started at T43 but did not contain any other modifications. Recombinant baculoviruses were generated using a modified pFastBac1 transfer plasmid (Invitrogen). Trichoplusia ni cells were infected at a cell density of 0.8-1 million cells per ml with recombinant virus at a multiplicity of infection (MOI) of 5, and the temperature was lowered from 28 uC to 21 uC. Cells were collected by centrifugation 48 h after infection, re-suspended in hypotonic buffer (10 mM HEPES pH 7.5, 10 mM MgCl 2 , 20 mM KCl), flash-frozen in liquid nitrogen and stored at -80 uC until use. Preparation of urea-washed P2 insect cell membranes. NTSR1-enriched membranes were obtained as a P2 fraction from insect cells 46, 47 . Prior to G protein coupling assays and agonist binding experiments, the P2 membranes were treated with urea to remove peripherally bound membrane proteins 48, 49 . The receptor density in urea-washed P2 membranes was determined by [ 3 H]NTS saturation binding analysis 47 .
Stability tests in detergent solution. Cell pellets from 10 ml of insect cell cultures (NTSR1-GW5-T4L; cell density at harvest ,1.5-2.5 million cells per ml with ,10 million receptors per cell) or P2 membranes (wild-type NTSR1) were re-suspended in 2 ml buffer containing DM or LMNG/CHS to give a final buffer composition of 50 mM TrisHCl pH 7.4, 200 mM NaCl, 1% DM or 1% LMNG/ 0.1% CHS. The samples were placed on a rotating mixer at 4 uC for 1 h. Cell debris and non-solubilized material were removed by ultracentrifugation (TL120.2 rotor, 60,000 r.p.m., 4 uC, 30 min in Optima Max bench-top ultracentrifuge, Beckman), and the supernatants containing detergent-solubilized NTSR1 were used to test for thermal stability in the 1NTS format 47 . For thermal denaturation curves, the supernatants were diluted 6.67-fold into assay buffer (50 mM TrisHCl pH 7.4, 200 mM NaCl) containing 10 nM [ 3 H]NTS and incubated for 1-2.5 h on ice to allow [ 3 H]NTS binding to NTSR1. Samples (120 ml aliquots) were exposed to different temperatures between 0 uC and 70 uC for 30 min and placed on ice. Separation of receptor-ligand complex from free ligand (100 ml) was achieved by centrifugation-assisted gel filtration (spin assay) using Bio-Spin 30 Tris columns, equilibrated with RDB buffer (50 mM TrisHCl pH 7.4, 1 mM EDTA, 0.1% DDM, 0.2% CHAPS, 0.04% CHS). Control reactions on ice were recorded at the start and at the end of each denaturation experiment. The percentage of activity remaining after heat exposure was determined with respect to the unheated control. Data were analysed by nonlinear regression using a Boltzmann sigmoidal equation in Prism software (GraphPad). Ligand-binding experiments. All radio-ligand binding assays were conducted with urea-washed P2 insect cell membranes containing wild-type NTSR1, NTSR1-GW5-T4L or NTSR1-GW5. For agonist [ 3 H]NTS saturation binding experiments, receptors were incubated on ice for 1 h in 250 ml TEBB buffer (50 mM TrisHCl pH 7.4, 1 mM EDTA, 0.1% BSA, 0.004% bacitracin) containing [ 3 H]NTS at a concentration of 0.6-20 nM. Nonspecific [ 3 H]NTS binding was determined in the presence of 50 mM unlabelled NTS. Separation of bound from free ligand was achieved by rapid filtration through GF/B glass fibre filters (Whatman) pretreated with polyethylenimine. The amount of radioactivity was quantified by liquid scintillation counting (Beckman LS6500). Data were analysed by nonlinear regression using the GraphPad Prism software and best fit to a one-site binding equation to determine the equilibrium dissociation constant (K d ) for wild-type NTSR1/ 'apparent' dissociation constants for NTSR1-GW5-T4L and NTSR1-GW5. Note that the saturation binding experiments using wild-type NTSR1 were conducted at equilibrium. In contrast, binding of [ 3 H]NTS to NTSR1-GW5-T4L and NTSR1-GW5 did not reach equilibrium within the incubation time because of the very slow agonist off-rates.
Competition assays with the non-peptide antagonist SR48692 (ref. 50) were performed in the presence of [ 3 H]NTS (TEBB buffer, 5 nM [ 3 H]NTS, NTSR1 concentration ,0.5 nM, incubation for 2 h on ice, 250 ml assay volume). Data were fit to a sigmoidal dose-response equation with standard slope using the concentrations of total SR48692 added versus bound [ 3 H]NTS.
The effect of Na 1 ions on [ 3 H]NTS binding was measured with NaCl concentrations ranging from 0 to 1 M (TEBB buffer, 8 nM [ 3 H]NTS, NTSR1 concentration ,0.5 nM, incubation for 1.5 h on ice, 300 ml assay volume). Data were analysed by nonlinear regression using the GraphPad Prism four-parameter dose-response equation (variable slope) with the top and bottom plateaux constrained from 100-15% (wild-type NTSR1) and 100-50% (NTSR1-GW5-T4L, NTSR1-GW5), respectively.
The association of [ 3 H]NTS was assessed at a concentration of 10 nM (TEBB buffer, NTSR1 concentration ,0.5 nM). At the indicated time points, 250 ml aliquots were filtered over glass fibre filters. After 2 h, [ 3 H]NTS dissociation was initiated by adding 41.7 mM unlabelled NTS or by addition of 41.7 mM NTS and 833 mM NaCl; this step reduced the concentration of [ 3 H]NTS to 8 nM. Samples were subjected to filtration after the indicated time points. No attempt was made to compare quantitatively the observed rates of association and the dissociation rate constants between NTSR1 constructs because of the very fast association of agonist to wild-type NTSR1, the very fast dissociation of agonist from wild-type NTSR1 in the presence of NaCl, and the very slow dissociation of [ 3 H]NTS from NTSR1-GW5-T4L and NTSR1-GW5. GTP-cS assays. Before G protein coupling assays, the P2 membranes were treated with urea to remove peripherally bound membrane proteins 48, 49 . GDP/[ 35 S]GTP-cS exchange assays were performed as previously described 47 with 1 nM receptor, 100 nM Ga q (purified from dark-adapted Sepia officinalis retina 48 ), 500 nM Gb 1 c 1 (purified from bovine retina 51 ), and 10 mM NTS, 40 mM nonpeptide antagonist SR48692 (ref. 50) or no ligand in the reaction (5 min at 30 uC). Large-scale purification of NTSR1-GW5-T4L from insect cell membranes. Cells from 3 l of insect cell culture were thawed and the volume was brought to approximately 240 ml with hypotonic buffer (10 mM HEPES pH 7.5, 10 mM MgCl 2 , 20 mM KCl). The cells were then re-suspended using a Turrax T-25 (IKA) homogenizer at 8,200 r.p.m. for 2 min. After centrifugation (45Ti rotor, 40,000 r.p.m., 45 min, 4 uC, Optima L90K, Beckman), the membranes were resuspended (Turrax T-25) in approximately 240 ml of high-salt buffer (10 mM HEPES pH 7.5, 1 M NaCl, 10 mM MgCl 2 , 20 mM KCl) supplemented with DNase I (final concentration 10 mg ml 21 ) and AEBSF (100 mM), and centrifuged again. All subsequent steps were performed at 4 uC or on ice, and AEBSF (100 mM final concentration) was repeatedly added throughout the procedure. The washed membranes were re-suspended in 60 ml of buffer (100 mM TrisHCl pH 7.4, 60% glycerol) containing 20 mM NTS [8] [9] [10] [11] [12] [13] , and stirred for 45 min to allow agonist binding to membrane-inserted NTSR1-GW5-T4L. The receptor was extracted by drop-wise addition of 40 ml of a 3% LMNG/0.3% CHS solution. After 1 h, NaCl was added, and the solution was gently stirred for an additional hour. The final volume was 120 ml containing 50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 1% LMNG/0.1% CHS and 10 mM NTS [8] [9] [10] [11] [12] [13] . The sample was clarified by centrifugation (45Ti rotor, 40,000 r.p.m., 1 h, Optima L90K, Beckman), adjusted with imidazole to a final concentration of 20 mM, and then passed through a 0.2 mm filter (Stericup). Next, the sample was loaded at a flow rate of 0.2 ml min 21 onto 2.5 ml Talon resin packed into an XK16 column (GE Healthcare) equilibrated with Talon-A 1 buffer (50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 20 mM imidazole, 1 mM NTS 8-13 , 0.1% LMNG/0.01% CHS). After washing with 29 column volumes of buffer Talon-A 1 , NTSR1-GW5-T4L was eluted with Talon-B 1 buffer (50 mM TrisHCl pH 7.4, 30% glycerol, 500 mM NaCl, 200 mM imidazole, 5 mM NTS 8-13 , 0.1% LMNG/0.01% CHS). Peak fractions were collected (5 ml) and desalted using PD10 columns equilibrated in PD10 buffer (20 mM TrisHCl pH 7.4, 100 mM NaCl, 0.003% LMNG/0.0003% CHS). NTS [8] [9] [10] [11] [12] [13] was then added to a concentration of 10 mM, and the sample was used for crystallization. Three litres of insect cell culture yielded ,1.7 mg of purified NTSR1-GW5-T4L. Crystallization. Purified desalted NTSR1-GW5-T4L was diluted fourfold into buffer (25 mM TrisHCl pH 7.4, 100 mM NaCl) containing 100 mM TCEP and then concentrated to an estimated 20-25 mg ml 21 using a 100,000 MWCO concentrator (Amicon Ultra, Millipore). After addition of NTS 8-13 to 1 mM and centrifugation (TLA 120.1 rotor, 60,000 r.p.m., 15 min, 8 uC, Beckman), the sample was mixed with 1.5 parts by weight of a mix of monoolein with RESEARCH ARTICLE cholesterol (10:1) using the two-syringe method 52 . The resulting lipidic cubic phase 53 mix was dispensed in 65-nl drops onto Laminex plates (Molecular Dimensions) and overlaid with 750-nl precipitant solution. Crystals grew after 1 week in precipitant solution consisting of 20.8% PEG 400, 80 mM HEPES pH 7.0, 2 mM TCEP and 43 mM NaK tartrate. Crystals were collected directly from LCP using 50 mm micro-loops (M5-L18SP-50, MiTeGen) and immediately flash frozen in liquid nitrogen without adding extra cryoprotectant. Data collection and structure determination. Data collection was performed with the JBluIce-EPICS data acquisition software at the GM/CA-CAT (23-ID-B) beamline at the Advanced Photon Source of Argonne National Laboratory. Crystals within the loop were located by diffraction using the automated rastering module of JBluIce-EPICS 54, 55 . Most crystals showed diffraction spots to ,4-5 Å ; a few crystals diffracted to ,3-3.5 Å with a single crystal showing diffraction to ,2.6 Å . A single data set was collected from this crystal containing 150 frames with an oscillation of 1 degree per frame and was processed in space group P2 1 to 2.80 Å with an overall completeness of 93.1%.
Structure determination was performed by molecular replacement using the Phaser-MR module of PHENIX 56 . Two search models were created using the structure of b 2 AR 57 (PDB code 3NY9) with one containing the T4 lysozyme domain and one containing the receptor seven-helix bundle without side chains. One copy of each search model was found, producing a single solution. Subsequent refinement was performed by PHENIX 56 and model building with COOT 58 . Strong difference density was observed within the ligand-binding cavity which we were able to model unambiguously as the six-residue neurotensin peptide RRPYIL (NTS [8] [9] [10] [11] [12] [13] ). The structure was refined with final R/R free values of 0.23/0.28. A summary of data collection and refinement statistics is reported in Supplementary Table 3 .
We noted during the later stages of structure determination that no electron density was observed for the C-terminal carboxyl group of NTS [8] [9] [10] [11] [12] [13] (using an F o 2 F c map contoured at ,0.1 e 2 Å 23 , ,2s) despite clear electron density for the rest of the agonist peptide. However, relatively strong density was found in close proximity to the modelled C-terminal carboxyl group of L13 ( Supplementary  Fig. 12 ). We interpreted the lack of density for the modelled C-terminal carboxyl group of NTS [8] [9] [10] [11] [12] [13] and the presence of electron density close by as a probable result of decarboxylation caused by radiation damage 59, 60 (estimated absorbed dose over 150 frames ,314 MGy, 103 experimental dose limit, RADDOSE 61 ) with the cleaved entity being stabilized by a potential salt-bridge-like interaction with R327. However, for the purpose of understanding the biology and the interactions involved in agonist binding by NTSR1 in vivo, that is, in the absence of radiation damage, and to minimize any confusion for those scientists who may not be familiar with X-ray crystallography yet who may view the NTSR1-GW5-T4L structure, we have chosen to model NTS [8] [9] [10] [11] [12] [13] with a carboxyl group at its C terminus in the final NTSR1-GW5-T4L model.
Figures were prepared in PyMOL (Schrödinger). Structural alignments were done with the 'align' command of PyMOL.
